Back to today’s briefing

Story perspectives

FDA Panel Debates Antidepressants: Risks vs. Untreated Depression

7/29/2025

34 6

Summary

Story summary

The FDA panel's recent discussion on antidepressant use during pregnancy revealed a complex dilemma, weighing the risks to mothers and their babies against the perils of untreated depression. With experts divided, the conversation underscores the urgent need for open dialogue between healthcare providers and patients, bridging cultural divides in mental health care.

1 of 1

Story summary

The FDA panel's recent discussion on antidepressant use during pregnancy revealed a complex dilemma, weighing the risks to mothers and their babies against the perils of untreated depression. With experts divided, the conversation underscores the urgent need for open dialogue between healthcare providers and patients, bridging cultural divides in mental health care.